You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNifedipine
Accession NumberDB01115  (APRD00590)
TypeSmall Molecule
GroupsApproved
DescriptionNifedipine has been formulated as both a long- and short-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nifedipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Nifedipine is used to treat hypertension and chronic stable angina.
Structure
Thumb
Synonyms
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester
Adalat
Adapine
Coracten
Nifecard
Nifecor
Nifedipine
Nifedipino
Nifedipinum
Nifedipres
Procardia
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdalatCapsule5 mgOralBayer Inc1997-01-072005-07-27Canada
Adalat - Cap 10mgCapsule10 mgOralBayer Inc1982-12-312005-07-27Canada
Adalat Cap 10mgCapsule10 mgOralMiles Canada Inc. Pharmaceutical Division1982-12-312000-08-01Canada
Adalat Cap 5mgCapsule5 mgOralMiles Canada Inc. Pharmaceutical Division1986-12-312000-08-01Canada
Adalat CcTablet, film coated30 mg/1OralBayer Health Care Pharmaceuticals Inc.1993-04-21Not applicableUs
Adalat CcTablet, film coated60 mg/1OralBayer Health Care Pharmaceuticals Inc.1993-04-21Not applicableUs
Adalat CcTablet, film coated30 mg/1OralALMATICA PHARMA INC.2016-10-25Not applicableUs
Adalat CcTablet, film coated90 mg/1OralBayer Health Care Pharmaceuticals Inc.1993-04-21Not applicableUs
Adalat CcTablet, film coated90 mg/1OralAphena Pharma Solutions Tennessee, Llc1993-04-21Not applicableUs
Adalat OrosTablet, extended release30 mgOralBayer IncNot applicableNot applicableCanada
Adalat OrosTablet, extended release60 mgOralBayer IncNot applicableNot applicableCanada
Adalat OrosTablet, extended release20 mgOralBayer IncNot applicableNot applicableCanada
Adalat P.A.10 -srt 10mgTablet, extended release10 mgOralBayer Inc1989-12-302005-07-27Canada
Adalat P.A.20 -srt 20mgTablet, extended release20 mgOralBayer Inc1997-07-182005-07-27Canada
Adalat Pa 10 Tab 10mgTablet10 mgOralMiles Canada Inc. Pharmaceutical Division1989-12-312000-08-01Canada
Adalat Pa 20Tablet20 mgOralMiles Canada Inc. Pharmaceutical Division1987-12-312000-08-01Canada
Adalat XL - Srt 20mgTablet, extended release20 mgOralBayer Inc1998-05-05Not applicableCanada
Adalat XL - Srt 30mgTablet, extended release30 mgOralBayer Inc1992-12-31Not applicableCanada
Adalat XL - Srt 60mgTablet, extended release60 mgOralBayer Inc1992-12-31Not applicableCanada
Adalat XL Tab 30mgTablet, extended release30 mgOralMiles Canada Inc. Pharmaceutical Division1992-12-311996-10-02Canada
Adalat XL Tab 60mgTablet, extended release60 mgOralMiles Canada Inc. Pharmaceutical Division1992-12-311996-10-02Canada
Afeditab CRTablet, extended release60 mg/60mgOralRemedy Repack2010-05-13Not applicableUs
Dom-nifedipineCapsule5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-nifedipineCapsule10 mgOralDominion PharmacalNot applicableNot applicableCanada
Gen Nifedipine Cap 10mg USPCapsule10 mgOralGenpharm Ulc1991-12-312009-08-05Canada
Mylan-nifedipine Extended ReleaseTablet, extended release60 mgOralMylan Pharmaceuticals Ulc2008-12-30Not applicableCanada
Mylan-nifedipine Extended ReleaseTablet, extended release30 mgOralMylan Pharmaceuticals Ulc2010-04-23Not applicableCanada
NifedipineCapsule10 mg/1OralGreenstone LLC2013-03-25Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralA S Medication Solutions2010-03-31Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralREMEDYREPACK INC.2014-06-16Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralREMEDYREPACK INC.2015-11-12Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralA S Medication Solutions1993-04-21Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralAlvogen, Inc.1993-04-21Not applicableUs
NifedipineCapsule5 mgOralAa Pharma Inc1989-12-31Not applicableCanada
NifedipineTablet, film coated, extended release30 mg/1OralGreenstone LLC2010-03-31Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralA S Medication Solutions2010-03-31Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralContract Pharmacy Services Pa2010-04-13Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralAlvogen, Inc.1993-04-21Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralGreenstone LLC2010-03-31Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralA S Medication Solutions1993-04-21Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralA S Medication Solutions1993-04-21Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralPhysicians Total Care, Inc.2003-08-11Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralAlvogen, Inc.1993-04-21Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralGreenstone LLC2010-03-31Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralA S Medication Solutions1993-04-21Not applicableUs
NifedipineCapsule10 mgOralAa Pharma Inc1988-12-31Not applicableCanada
NifedipineTablet, film coated, extended release60 mg/1OralA S Medication Solutions1993-04-21Not applicableUs
Nifedipine 10mg - CapCapsule10 mgOralSchein Pharmaceutical Canada Inc.1996-12-311998-08-14Canada
Nifedipine 5mg - CapCapsule5 mgOralSchein Pharmaceutical Canada Inc.1995-12-311998-08-14Canada
Nifedipine Capsules 10mgCapsule10 mgOralPrempharm Inc1997-01-052005-08-05Canada
Nifedipine ERTablet, extended release60 mgOralSivem Pharmaceuticals Ulc2015-09-29Not applicableCanada
Nifedipine ERTablet, extended release30 mgOralPro Doc Limitee2015-01-13Not applicableCanada
Nifedipine ERTablet, extended release20 mgOralPro Doc LimiteeNot applicableNot applicableCanada
Nifedipine ERTablet, extended release30 mgOralSivem Pharmaceuticals Ulc2015-09-29Not applicableCanada
Nifedipine ERTablet, extended release60 mgOralPro Doc Limitee2015-01-13Not applicableCanada
Nifedipine Pa -10 - Srt 10mgTablet, extended release10 mgOralPro Doc Limitee1996-12-062009-07-23Canada
Nifedipine Pa 10 - Srt 10mgTablet, extended release10 mgOralSchein Pharmaceutical Canada Inc.1995-12-312004-07-26Canada
Nifedipine Pa 20 - Srt 20mgTablet, extended release20 mgOralSchein Pharmaceutical Canada Inc.1995-12-312004-07-26Canada
Nifedipine Pa-20 - Srt 20mgTablet, extended release20 mgOralPro Doc Limitee1996-12-062009-07-23Canada
Nifedipine-10 Cap 10mgCapsule10 mgOralPro Doc Limitee1988-12-312000-07-31Canada
Novo-nifedin Cap 10mgCapsule10 mgOralNovopharm Limited1987-12-312005-08-10Canada
Novo-nifedin Cap 5mgCapsule5 mgOralNovopharm Limited1993-12-312005-08-10Canada
Novo-nifedin XLTablet, extended release20 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-nifedin XLTablet, extended release30 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-nifedin XLTablet, extended release60 mgOralNovopharm LimitedNot applicableNot applicableCanada
Nu-nifed Cap 10mgCapsule10 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-nifedipine-PATablet, extended release20 mgOralNu Pharm Inc1997-01-212012-09-04Canada
Nu-nifedipine-PA - Prolonged Action TabTablet, extended release10 mgOralNu Pharm Inc1997-01-212012-09-04Canada
PMS-nifedipineCapsule5 mgOralPharmascience Inc1997-10-24Not applicableCanada
PMS-nifedipineCapsule10 mgOralPharmascience Inc1997-10-24Not applicableCanada
PMS-nifedipine ERTablet, extended release20 mgOralPharmascience Inc2015-07-22Not applicableCanada
PMS-nifedipine ERTablet, extended release60 mgOralPharmascience Inc2015-03-17Not applicableCanada
PMS-nifedipine ERTablet, extended release30 mgOralPharmascience Inc2015-03-17Not applicableCanada
ProcardiaCapsule10 mg/1OralPfizer Laboratories Div Pfizer Inc1981-12-31Not applicableUs
ProcardiaCapsule10 mg/1OralREMEDYREPACK INC.2013-02-25Not applicableUs
Procardia XLTablet, film coated, extended release30 mg/1OralPfizer Laboratories Div Pfizer Inc1989-09-06Not applicableUs
Procardia XLTablet, film coated, extended release60 mg/1OralPfizer Laboratories Div Pfizer Inc1989-09-06Not applicableUs
Procardia XLTablet, film coated, extended release90 mg/1OralPfizer Laboratories Div Pfizer Inc1989-09-06Not applicableUs
Procardia XLTablet, film coated, extended release30 mg/1OralCardinal Health1989-09-06Not applicableUs
Taro-nifedipine Cap 10mgCapsule10 mgOralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Afeditab CRTablet, film coated, extended release30 mg/1OralActavis Pharma, Inc.2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release60 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release30 mg/1OralCarilion Materials Management2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release60 mg/1OralActavis Pharma, Inc.2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release30 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-11-01Not applicableUs
Afeditab CRTablet, film coated, extended release60 mg/1Oralbryant ranch prepack2002-11-01Not applicableUs
Apo-nifed Pa - Srt 20mgTablet, extended release20 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-nifed Pa - Tab 10mgTablet10 mgOralApotex Inc1995-12-31Not applicableCanada
Nifediac CcTablet, film coated, extended release90 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifediac CcTablet, film coated, extended release90 mg/1Oralbryant ranch prepack2002-09-16Not applicableUs
Nifediac CcTablet, film coated, extended release30 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Nifedical XLTablet, film coated, extended release30 mg/1Oralbryant ranch prepack2001-02-09Not applicableUs
Nifedical XLTablet, film coated, extended release60 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Nifedical XLTablet, film coated, extended release60 mg/1Oralbryant ranch prepack2000-12-11Not applicableUs
Nifedical XLTablet, film coated, extended release60 mg/1OralCardinal Health2000-12-11Not applicableUs
Nifedicalxl XLTablet, film coated, extended release30 mg/1OralAidarex Pharmaceuticals LLC2001-02-09Not applicableUs
Nifedicalxl XLTablet, film coated, extended release60 mg/1OralAidarex Pharmaceuticals LLC2000-12-11Not applicableUs
NifedipineTablet, extended release90 mg/1OralTWI Pharmaceuticals, Inc.2014-11-01Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralREMEDYREPACK INC.2014-07-29Not applicableUs
NifedipineTablet, extended release60 mg/1OralPhysicians Total Care, Inc.2009-03-05Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralAmerican Health Packaging2012-05-01Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralKremers Urban Pharmaceuticals Inc.2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralPar Pharmaceutical2016-07-13Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-23Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralSTAT Rx USA LLC1989-04-28Not applicableUs
NifedipineCapsule, liquid filled20 mg/1OralAv Pak2015-07-29Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
NifedipineTablet, extended release30 mg/1Oralbryant ranch prepack2009-10-05Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralCardinal Health1991-01-08Not applicableUs
NifedipineCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.2009-08-11Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralOceanside Pharmaceuticals2000-09-27Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralTeva Pharmaceuticals USA Inc2001-02-09Not applicableUs
NifedipineTablet, extended release90 mg/1OralTEVA PHARMACEUTICALS USA2013-08-022017-11-30Us
NifedipineTablet, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-11-01Not applicableUs
NifedipineCapsule20 mg/1OralLeading Pharma, Llc2016-11-23Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-06-28Not applicableUs
NifedipineTablet, extended release30 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralCardinal Health2007-06-20Not applicableUs
NifedipineTablet, extended release30 mg/1OralInternational Laboratories, Inc.2009-08-21Not applicableUs
NifedipineTablet, extended release90 mg/1OralActavis Inc.2012-05-29Not applicableUs
NifedipineTablet, extended release30 mg/1OralTYA Pharmaceuticals2012-10-18Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralClinical Solutions Wholesale2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralUnit Dose Services2005-11-21Not applicableUs
NifedipineTablet, extended release60 mg/1OralPreferred Pharmaceuticals, Inc.2016-10-24Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralMylan Pharmaceuticals Inc.2000-03-14Not applicableUs
NifedipineTablet, extended release60 mg/1OralRebel Distributors Corp2006-12-13Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralREMEDYREPACK INC.2013-05-14Not applicableUs
NifedipineTablet, extended release60 mg/1OralTWI Pharmaceuticals, Inc.2014-11-01Not applicableUs
NifedipineTablet, extended release30 mg/1OralPhysicians Total Care, Inc.2007-07-03Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralAmerican Health Packaging2012-05-01Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralKremers Urban Pharmaceuticals Inc.2007-10-03Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralPar Pharmaceutical2016-07-13Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-23Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralTeva Pharmaceuticals USA Inc2000-12-11Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralSTAT Rx USA LLC2011-06-28Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralMylan Institutional Inc.2010-09-13Not applicableUs
NifedipineTablet, extended release30 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-07-19Not applicableUs
NifedipineCapsule, liquid filled20 mg/1OralCardinal Health1990-09-20Not applicableUs
NifedipineCapsule10 mg/1OralAmerican Health Packaging2012-02-012015-12-29Us
NifedipineTablet, extended release30 mg/1OralOceanside Pharmaceuticals2012-10-18Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralAvera Mc Kennan Hospital2015-12-02Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralCardinal Health2007-11-06Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralMylan Pharmaceuticals Inc.2010-12-20Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralLegacy Pharmaceutical Packaging, Llc2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralREMEDYREPACK INC.2013-05-14Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralA S Medication Solutions Llc1991-01-01Not applicableUs
NifedipineTablet30 mg/1OralREMEDYREPACK INC.2011-10-172016-12-02Us
NifedipineTablet, film coated, extended release90 mg/1OralDispensing Solutions, Inc.2007-10-03Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralClinical Solutions Wholesale2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralUnit Dose Services2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralMylan Pharmaceuticals Inc.2000-03-14Not applicableUs
NifedipineCapsule10 mg/1OralHeritage Pharmaceuticals Inc.2010-12-07Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-06-30Not applicableUs
NifedipineTablet, extended release30 mg/1OralTWI Pharmaceuticals, Inc.2014-11-01Not applicableUs
NifedipineTablet, extended release60 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralAmerican Health Packaging2012-05-01Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralIVC Industries, Inc. dba Inverness Medical Nutritionals Group2009-08-01Not applicableUs
NifedipineTablet, extended release30 mg/1OralTEVA PHARMACEUTICALS USA2012-10-182018-01-31Us
NifedipineCapsule, liquid filled10 mg/1OralA S Medication Solutions1991-01-01Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-23Not applicableUs
NifedipineTablet, extended release60 mg/1OralA S Medication Solutions2014-11-01Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralActavis Pharma, Inc.1991-01-01Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralRebel Distributors Corp2007-10-03Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralMylan Institutional Inc.2010-10-01Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-07-23Not applicableUs
NifedipineTablet, extended release60 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-07-19Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralPd Rx Pharmaceuticals, Inc.2005-11-21Not applicableUs
NifedipineTablet, extended release60 mg/1OralOceanside Pharmaceuticals2000-12-04Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralRebel Distributors Corp2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralCardinal Health2010-06-23Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralMylan Pharmaceuticals Inc.2010-12-20Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralLegacy Pharmaceutical Packaging, Llc2005-11-21Not applicableUs
NifedipineCapsule20 mg/1OralHeritage Pharmaceuticals Inc.2010-12-07Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralREMEDYREPACK INC.2013-06-03Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralPhysicians Total Care, Inc.2009-01-29Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralAmerican Health Packaging2013-06-05Not applicableUs
NifedipineCapsule10 mg/1OralGolden State Medical Supply, Inc.2009-08-11Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralKremers Urban Pharmaceuticals Inc.2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralPar Pharmaceutical2016-07-13Not applicableUs
NifedipineTablet, extended release30 mg/1OralNu Care Pharmaceuticals, Inc.2014-11-01Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralMylan Pharmaceuticals Inc.2000-03-14Not applicableUs
NifedipineTablet, extended release90 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-08-02Not applicableUs
NifedipineCapsule10 mg/1OralLeading Pharma, Llc2016-11-23Not applicableUs
NifedipineTablet, film coated, extended release60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-06-30Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralAidarex Pharmaceuticals LLC2007-10-03Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralCardinal Health2013-06-05Not applicableUs
NifedipineCapsule, liquid filled20 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
NifedipineCapsule10 mg/1Oralbryant ranch prepack2009-08-11Not applicableUs
NifedipineTablet, extended release60 mg/1OralTEVA PHARMACEUTICALS USA2012-11-082017-11-30Us
NifedipineTablet, extended release90 mg/1OralOceanside Pharmaceuticals2002-08-16Not applicableUs
NifedipineTablet, extended release30 mg/1OralA S Medication Solutions2012-10-182018-01-31Us
NifedipineCapsule, liquid filled20 mg/1OralActavis Pharma, Inc.1990-09-20Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralRebel Distributors Corp2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralMylan Institutional Inc.2010-08-20Not applicableUs
NifedipineTablet, extended release60 mg/1OralInternational Laboratories, Inc.2009-08-22Not applicableUs
NifedipineCapsule10 mg/1OralGAVIS Pharmaceuticals, LLC2009-08-11Not applicableUs
NifedipineTablet, extended release30 mg/1OralMc Kesson Packaging Servives A Business Unit Of Mc Kesson Corporation2011-07-01Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralClinical Solutions Wholesale2005-11-21Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-07-23Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralCardinal Health2010-06-23Not applicableUs
NifedipineCapsule, liquid filled10 mg/1OralAv Pak2015-07-29Not applicableUs
NifedipineCapsule10 mg/1OralCarilion Materials Management2009-08-11Not applicableUs
NifedipineTablet, film coated, extended release90 mg/1OralMylan Pharmaceuticals Inc.2010-12-20Not applicableUs
NifedipineTablet, film coated, extended release30 mg/1OralOceanside Pharmaceuticals2000-09-27Not applicableUs
Nifedipine ERTablet, film coated, extended release30 mg/1OralAv Pak2005-11-21Not applicableUs
Nifedipine ERTablet, film coated, extended release60 mg/1OralAv Pak2005-11-21Not applicableUs
Nifedipine ERTablet, film coated, extended release90 mg/1OralAv Pak2007-10-03Not applicableUs
Nifedipine Extended ReleaseTablet, extended release60 mg/1OralPar Pharmaceutical, Inc.2007-06-22Not applicableUs
Nifedipine Extended ReleaseTablet, extended release30 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Nifedipine Extended ReleaseTablet, extended release30 mg/1OralMajor Pharmaceuticals2007-06-22Not applicableUs
Nifedipine Extended ReleaseTablet, extended release90 mg/1OralPar Pharmaceutical, Inc.2012-05-29Not applicableUs
Nifedipine Extended ReleaseTablet, extended release60 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Nifedipine Extended ReleaseTablet, extended release90 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-05-29Not applicableUs
Nifedipine Extended ReleaseTablet, extended release60 mg/1OralMajor Pharmaceuticals2007-06-22Not applicableUs
Nifedipine Extended ReleaseTablet, extended release30 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Nifedipine Extended ReleaseTablet, extended release90 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Nifedipine Extended ReleaseTablet, extended release30 mg/1OralPar Pharmaceutical, Inc.2007-06-22Not applicableUs
Nifedipine Extended ReleaseTablet, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-06-22Not applicableUs
Nifedipine Extended-releaseTablet, extended release30 mg/1OralPar Pharmaceutical, Inc.2014-04-03Not applicableUs
Nifedipine Extended-releaseTablet, extended release60 mg/1OralPar Pharmaceutical, Inc.2014-04-03Not applicableUs
Nifedipine Extended-releaseTablet, extended release90 mg/1OralPar Pharmaceutical, Inc.2014-04-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdapineNot Available
AfeditabNot Available
CoractenNot Available
NifecardNot Available
NifecorNot Available
NifedicalNot Available
NifedicalXLNot Available
NifedipresNot Available
Brand mixtures
NameLabellerIngredients
Adalat XL PlusBayer Inc
SaltsNot Available
Categories
UNIII9ZF7L6G2L
CAS number21829-25-4
WeightAverage: 346.3346
Monoisotopic: 346.116486318
Chemical FormulaC17H18N2O6
InChI KeyHYIMSNHJOBLJNT-UHFFFAOYSA-N
InChI
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
IUPAC Name
3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC
Pharmacology
IndicationFor the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
Structured Indications
PharmacodynamicsNifedipine, the prototype of the dihydropyridine class of calcium channel blockers (CCBs), is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, nifedipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives nifedipine additional arterial selectivity. At therapeutic sub-toxic concentrations, nifedipine has little effect on cardiac myocytes and conduction cells. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.
Mechanism of actionNifedipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. The vasodilatory effects of nifedipine result in an overall decrease in blood pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent calcium channel subunit alpha-2/delta-1Proteinyes
inhibitor
HumanP54289 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinyes
inhibitor
HumanQ13698 details
CalmodulinProteinunknown
inhibitor
HumanP62158 details
Potassium voltage-gated channel subfamily A member 1Proteinunknown
inhibitor
HumanQ09470 details
Voltage-dependent T-type calcium channel subunit alpha-1HProteinunknown
inhibitor
HumanO95180 details
Related Articles
AbsorptionRapidly and fully absorbed following oral administration.
Volume of distributionNot Available
Protein binding92-98%
Metabolism

Hepatic metabolism via cytochrome P450 system. Predominantly metabolized by CYP3A4, but also by CYP1A2 and CYP2A6 isozymes.

SubstrateEnzymesProduct
Nifedipine
dehydronifedipineDetails
Route of eliminationNifedipine is extensively metabolized to highly water-soluble, inactive metabolites accounting for 60 to 80% of the dose excreted in the urine. The remainder is excreted in the feces in metabolized form, most likely as a result of biliary excretion.
Half life2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include dizziness, drowsiness, nausea, severe drop in blood pressure, slurred speech, and weakness. LD50=494 mg/kg (orally in mice); LD50=1022 mg/kg (orally in rats)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nifedipine Action PathwayDrug actionSMP00379
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nifedipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nifedipine.Vet Approved
AbirateroneThe serum concentration of Nifedipine can be increased when it is combined with Abiraterone.Approved
AcebutololNifedipine may increase the hypotensive activities of Acebutolol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Nifedipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Nifedipine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Nifedipine.Approved
AlbendazoleThe serum concentration of Nifedipine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Nifedipine.Experimental
AlectinibThe serum concentration of Nifedipine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Nifedipine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Nifedipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nifedipine is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Nifedipine.Approved, Investigational
AlprenololNifedipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Nifedipine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Nifedipine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nifedipine.Approved
Aminohippuric acidThe serum concentration of Nifedipine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Nifedipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Nifedipine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nifedipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nifedipine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nifedipine.Approved
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nifedipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nifedipine.Approved, Investigational
AmprenavirThe serum concentration of Nifedipine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Nifedipine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Nifedipine is combined with Amyl Nitrite.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nifedipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nifedipine.Approved, Investigational
Aop200704Nifedipine may increase the hypotensive activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Nifedipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nifedipine.Approved
AprepitantThe serum concentration of Nifedipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Nifedipine.Approved, Investigational
ArotinololNifedipine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nifedipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nifedipine.Approved
AstemizoleThe serum concentration of Nifedipine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Nifedipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololNifedipine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Nifedipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Nifedipine can be increased when it is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nifedipine is combined with Atosiban.Approved
Atracurium besylateNifedipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Nifedipine.Approved, Investigational
AzelastineThe serum concentration of Nifedipine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Nifedipine can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nifedipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nifedipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Nifedipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Barnidipine.Approved
BefunololNifedipine may increase the hypotensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nifedipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nifedipine.Approved
BenzocaineThe serum concentration of Nifedipine can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nifedipine.Approved
BepridilThe serum concentration of Nifedipine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Nifedipine.Approved, Vet Approved
BetaxololNifedipine may increase the hypotensive activities of Betaxolol.Approved
BevantololNifedipine may increase the hypotensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Nifedipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nifedipine.Approved
BiperidenThe serum concentration of Nifedipine can be increased when it is combined with Biperiden.Approved
BisoprololNifedipine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe metabolism of Nifedipine can be decreased when combined with Boceprevir.Approved
BopindololNifedipine may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe metabolism of Nifedipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nifedipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nifedipine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nifedipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Nifedipine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nifedipine.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Nifedipine.Approved, Investigational
BucindololNifedipine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolNifedipine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nifedipine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Bupivacaine.Approved, Investigational
BupranololNifedipine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Nifedipine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Nifedipine can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Nifedipine can be increased when it is combined with Buspirone.Approved, Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nifedipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nifedipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Nifedipine.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Nifedipine.Approved
CalciumThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Nifedipine.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nifedipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nifedipine.Withdrawn
CaptoprilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Captopril.Approved
CarbamazepineThe serum concentration of Nifedipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Carbetocin.Approved
CarbomycinThe metabolism of Nifedipine can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Nifedipine.Approved
CarteololNifedipine may increase the hypotensive activities of Carteolol.Approved
CarvedilolNifedipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nifedipine.Approved
CelecoxibThe metabolism of Nifedipine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololNifedipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nifedipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Nifedipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nifedipine.Approved
ChloroquineThe serum concentration of Nifedipine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nifedipine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Nifedipine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Nifedipine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Nifedipine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nifedipine.Approved
CholecalciferolThe metabolism of Nifedipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Nifedipine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Nifedipine can be decreased when it is combined with Cholic Acid.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nifedipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Nifedipine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Nifedipine can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Nifedipine.Approved, Investigational
CisaprideThe serum concentration of Nifedipine can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Nifedipine.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Nifedipine.Approved
ClarithromycinThe metabolism of Nifedipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nifedipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Nifedipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Nifedipine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Nifedipine.Approved, Investigational
ClomipramineThe serum concentration of Nifedipine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nifedipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nifedipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nifedipine.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Nifedipine.Approved
CobicistatThe serum concentration of Nifedipine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Nifedipine.Approved
CocaineThe metabolism of Nifedipine can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nifedipine.Approved
ColforsinThe serum concentration of Nifedipine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Nifedipine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nifedipine.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nifedipine.Investigational
CrizotinibThe metabolism of Nifedipine can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Nifedipine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nifedipine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Nifedipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Nifedipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nifedipine.Approved
DabrafenibThe serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Nifedipine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Nifedipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nifedipine.Investigational
DarifenacinThe metabolism of Nifedipine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nifedipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Nifedipine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Nifedipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Nifedipine.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nifedipine.Experimental
DeferasiroxThe serum concentration of Nifedipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nifedipine can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Nifedipine is combined with Desflurane.Approved
DesipramineThe serum concentration of Nifedipine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Nifedipine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Nifedipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nifedipine.Approved, Vet Approved
DextromethorphanThe serum concentration of Nifedipine can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Nifedipine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Nifedipine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nifedipine.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Nifedipine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nifedipine.Approved
DihydroergotamineThe metabolism of Nifedipine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Nifedipine.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nifedipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Nifedipine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nifedipine.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Nifedipine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Nifedipine.Approved, Investigational, Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nifedipine.Approved
DoxepinThe serum concentration of Nifedipine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nifedipine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Nifedipine.Approved, Investigational
DoxycyclineThe metabolism of Nifedipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Nifedipine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Nifedipine can be decreased when combined with Dronedarone.Approved
DuloxetineNifedipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nifedipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nifedipine.Approved
EfavirenzThe serum concentration of Nifedipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nifedipine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Nifedipine can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Nifedipine.Approved, Investigational
EliglustatThe metabolism of Nifedipine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nifedipine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Nifedipine is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Nifedipine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Nifedipine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nifedipine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Nifedipine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nifedipine.Approved
ErgonovineThe serum concentration of Nifedipine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Nifedipine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Nifedipine.Approved, Investigational
ErythromycinThe metabolism of Nifedipine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Nifedipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololNifedipine may increase the hypotensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Nifedipine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Nifedipine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Nifedipine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Nifedipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nifedipine.Approved
EthanolThe serum concentration of Nifedipine can be increased when it is combined with Ethanol.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nifedipine.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Nifedipine.Approved
EtravirineThe serum concentration of Nifedipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nifedipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Nifedipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Nifedipine is combined with Fenoldopam.Approved
FentanylThe serum concentration of Nifedipine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nifedipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Nifedipine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Nifedipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nifedipine is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Nifedipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nifedipine.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nifedipine.Approved, Vet Approved
FlupentixolThe serum concentration of Nifedipine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Nifedipine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Nifedipine can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nifedipine.Approved
FluvoxamineThe metabolism of Nifedipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nifedipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nifedipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.Approved
FosphenytoinThe serum concentration of Nifedipine can be decreased when it is combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nifedipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nifedipine can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Nifedipine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Nifedipine.Approved
GenisteinThe serum concentration of Nifedipine can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Nifedipine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Nifedipine can be increased when it is combined with Glycerol.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nifedipine.Experimental
Gramicidin DThe serum concentration of Nifedipine can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Nifedipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Nifedipine.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nifedipine.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nifedipine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Nifedipine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nifedipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Nifedipine is combined with Halothane.Approved, Vet Approved
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nifedipine.Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Nifedipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nifedipine.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Nifedipine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Nifedipine.Approved
IdelalisibThe serum concentration of Nifedipine can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Nifedipine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Nifedipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Nifedipine.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Nifedipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nifedipine.Approved
IndenololNifedipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nifedipine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Nifedipine.Approved, Investigational
IndoraminIndoramin may increase the hypotensive activities of Nifedipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nifedipine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Nifedipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nifedipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Nifedipine is combined with Isocarboxazid.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nifedipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nifedipine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Nifedipine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nifedipine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nifedipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nifedipine.Approved
ItraconazoleThe metabolism of Nifedipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nifedipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Nifedipine.Approved, Vet Approved
JosamycinThe metabolism of Nifedipine can be decreased when combined with Josamycin.Approved
KetamineThe serum concentration of Nifedipine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Nifedipine.Approved
KetoconazoleThe metabolism of Nifedipine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Nifedipine can be decreased when combined with Kitasamycin.Experimental
LabetalolNifedipine may increase the hypotensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Nifedipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Nifedipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Nifedipine.Approved, Investigational
LapatinibThe serum concentration of Nifedipine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Nifedipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Nifedipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Nifedipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Nifedipine.Approved, Investigational
LevobunololNifedipine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Levobupivacaine.Approved
LevodopaNifedipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Nifedipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Nifedipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nifedipine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Nifedipine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Nifedipine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Nifedipine.Approved
LiothyronineThe serum concentration of Nifedipine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Nifedipine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Nifedipine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Nifedipine.Approved
LopinavirThe metabolism of Nifedipine can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Nifedipine can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Nifedipine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nifedipine.Approved
LovastatinThe metabolism of Nifedipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nifedipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nifedipine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Nifedipine can be decreased when combined with Lumefantrine.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium Sulfate.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nifedipine.Approved, Investigational
MaprotilineThe serum concentration of Nifedipine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Nifedipine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nifedipine.Approved
MefloquineThe serum concentration of Nifedipine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Nifedipine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninMelatonin may decrease the antihypertensive activities of Nifedipine.Approved, Nutraceutical, Vet Approved
MeprobamateThe serum concentration of Nifedipine can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Nifedipine can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nifedipine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nifedipine.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Nifedipine.Approved
MethotrimeprazineThe metabolism of Nifedipine can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nifedipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nifedipine.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nifedipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Nifedipine.Approved, Vet Approved
MetipranololNifedipine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nifedipine.Approved, Investigational
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nifedipine.Experimental
MexiletineThe metabolism of Nifedipine can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Nifedipine can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nifedipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nifedipine.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Nifedipine.Approved, Illicit
MifepristoneThe serum concentration of Nifedipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nifedipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nifedipine.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Nifedipine.Approved
MitomycinThe serum concentration of Nifedipine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Nifedipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Nifedipine.Approved, Investigational
MivacuriumNifedipine may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Nifedipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nifedipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nifedipine.Vet Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Nifedipine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nifedipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nifedipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nabilone.Approved, Investigational
NadololNifedipine may increase the hypotensive activities of Nadolol.Approved
NafcillinThe metabolism of Nifedipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nifedipine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nifedipine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Nifedipine.Approved, Vet Approved
NaltrexoneThe serum concentration of Nifedipine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Nifedipine can be increased when it is combined with Naringenin.Experimental
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nifedipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Nifedipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nifedipine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Nifedipine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nifedipine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nifedipine can be decreased when it is combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nifedipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Nifedipine.Approved
NicotineThe metabolism of Nifedipine can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Nifedipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nifedipine.Approved
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Nifedipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nifedipine.Approved
NitrazepamThe serum concentration of Nifedipine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Nifedipine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nifedipine.Approved, Investigational
NitroprussideNifedipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nifedipine.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Nifedipine.Approved
NorethisteroneThe serum concentration of Nifedipine can be decreased when it is combined with Norethisterone.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nifedipine.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nifedipine is combined with Obinutuzumab.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Nifedipine.Approved, Investigational
OlaparibThe metabolism of Nifedipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Nifedipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nifedipine.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Nifedipine.Approved
OmeprazoleThe serum concentration of Nifedipine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Nifedipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nifedipine.Approved
OxprenololNifedipine may increase the hypotensive activities of Oxprenolol.Approved
P-NitrophenolThe serum concentration of Nifedipine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Nifedipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nifedipine.Investigational
PalbociclibThe serum concentration of Nifedipine can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Nifedipine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Nifedipine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Nifedipine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nifedipine.Approved
ParoxetineThe metabolism of Nifedipine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nifedipine.Approved
Peginterferon alfa-2bThe serum concentration of Nifedipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololNifedipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nifedipine.Approved
PentobarbitalThe serum concentration of Nifedipine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nifedipine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Nifedipine can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nifedipine.Approved, Vet Approved
PimozideThe serum concentration of Nifedipine can be increased when it is combined with Pimozide.Approved
PindololNifedipine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nifedipine is combined with Pipamperone.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Nifedipine.Approved
Platelet Activating FactorThe serum concentration of Nifedipine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Nifedipine.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Nifedipine.Approved
PosaconazoleThe metabolism of Nifedipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololNifedipine may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nifedipine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Nifedipine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nifedipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Nifedipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Nifedipine.Approved, Vet Approved
PrimidoneThe serum concentration of Nifedipine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Nifedipine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Nifedipine.Approved, Vet Approved
PromazineThe metabolism of Nifedipine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Nifedipine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Nifedipine can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Nifedipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololNifedipine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Nifedipine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nifedipine.Approved
QuercetinThe serum concentration of Nifedipine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Nifedipine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifedipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nifedipine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Nifedipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nifedipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nifedipine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Nifedipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nifedipine.Approved, Investigational
RapacuroniumNifedipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Nifedipine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Nifedipine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nifedipine.Approved
RifabutinThe serum concentration of Nifedipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Nifedipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nifedipine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nifedipine.Approved, Investigational
RilpivirineThe serum concentration of Nifedipine can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Nifedipine is combined with Riociguat.Approved
RisperidoneNifedipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Nifedipine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Nifedipine.Approved
RolapitantThe serum concentration of Nifedipine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Nifedipine.Approved, Investigational
RopiniroleThe metabolism of Nifedipine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nifedipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nifedipine.Approved, Vet Approved
SaquinavirThe metabolism of Nifedipine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nifedipine.Approved
ScopolamineThe serum concentration of Nifedipine can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Nifedipine.Approved, Vet Approved
SelegilineThe serum concentration of Nifedipine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Nifedipine.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nifedipine.Approved
SertralineThe serum concentration of Nifedipine can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nifedipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Nifedipine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nifedipine.Approved
SiltuximabThe serum concentration of Nifedipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nifedipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Nifedipine can be increased when it is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nifedipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nifedipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Nifedipine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Nifedipine is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Nifedipine.Approved
SolithromycinThe metabolism of Nifedipine can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Nifedipine.Approved, Investigational
SotalolNifedipine may increase the hypotensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Nifedipine.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Nifedipine.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nifedipine.Approved
St. John's WortThe serum concentration of Nifedipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Nifedipine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Nifedipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nifedipine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Nifedipine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nifedipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nifedipine.Approved
SulfinpyrazoneThe serum concentration of Nifedipine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Nifedipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Nifedipine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Nifedipine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Nifedipine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Nifedipine.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nifedipine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Nifedipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Nifedipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Nifedipine.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nifedipine.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Nifedipine.Approved
TelaprevirThe metabolism of Nifedipine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Nifedipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nifedipine.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Nifedipine.Approved
TenofovirThe metabolism of Nifedipine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Terazosin.Approved
TerbinafineThe metabolism of Nifedipine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nifedipine.Approved
TerfenadineThe serum concentration of Nifedipine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Nifedipine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Nifedipine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Nifedipine can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nifedipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Nifedipine can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Nifedipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nifedipine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nifedipine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nifedipine.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Nifedipine.Approved
TiclopidineThe metabolism of Nifedipine can be decreased when combined with Ticlopidine.Approved
TimololNifedipine may increase the hypotensive activities of Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nifedipine.Approved
TipranavirThe metabolism of Nifedipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Nifedipine.Approved
TocilizumabThe serum concentration of Nifedipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nifedipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nifedipine.Approved, Vet Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Nifedipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nifedipine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Nifedipine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nifedipine.Approved
TranylcypromineThe metabolism of Nifedipine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Nifedipine.Approved
TrazodoneThe serum concentration of Nifedipine can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nifedipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nifedipine.Approved
TrifluoperazineThe serum concentration of Nifedipine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Nifedipine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Nifedipine.Experimental
TrimethoprimThe serum concentration of Nifedipine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nifedipine.Approved, Investigational
TrimipramineThe serum concentration of Nifedipine can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe metabolism of Nifedipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Nifedipine can be decreased when combined with Tylosin.Vet Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Nifedipine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Nifedipine.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nifedipine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Nifedipine.Approved
VemurafenibThe serum concentration of Nifedipine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Nifedipine.Approved
VenlafaxineThe metabolism of Nifedipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nifedipine.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Nifedipine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nifedipine.Approved, Investigational
VinorelbineThe serum concentration of Nifedipine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Nifedipine.Approved
VoriconazoleThe metabolism of Nifedipine can be decreased when combined with Voriconazole.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Nifedipine.Approved
ZimelidineThe serum concentration of Nifedipine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Nifedipine can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Grapefruit down-regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take with low fat meal.
References
Synthesis Reference

Hiroitsu Kawata, Tadayoshi Ohmura, Katsuhiko Yano, Mikio Matsumura, Saburo Higuchi, Yoshiaki Soeishi, “Nifedipine-containing solid preparation composition.” U.S. Patent US4412986, issued November, 1976.

US4412986
General References
  1. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366-72. [PubMed:10972368 ]
  2. Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, van Dalen FJ, Lubsen J: Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006 Feb;20(1):45-54. [PubMed:16552473 ]
  3. Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H: Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther. 2005 Apr;30(2):153-8. [PubMed:15811168 ]
  4. Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996 Oct 23-30;276(16):1328-31. [PubMed:8861992 ]
  5. Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, Gunduz MG, Safak C, Yamada S: Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol Pharm Bull. 2008 Mar;31(3):473-9. [PubMed:18310913 ]
  6. Varon J, Marik PE: Clinical review: the management of hypertensive crises. Crit Care. 2003 Oct;7(5):374-84. Epub 2003 Jul 16. [PubMed:12974970 ]
External Links
ATC CodesC08CA05C08GA01C08CA55
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelDownload (206 KB)
MSDSDownload (74.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9073
Blood Brain Barrier-0.9536
Caco-2 permeable+0.7853
P-glycoprotein substrateNon-substrate0.5089
P-glycoprotein inhibitor IInhibitor0.8771
P-glycoprotein inhibitor IIInhibitor0.7902
Renal organic cation transporterNon-inhibitor0.9182
CYP450 2C9 substrateNon-substrate0.7776
CYP450 2D6 substrateNon-substrate0.5726
CYP450 3A4 substrateSubstrate0.705
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.6122
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.6715
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9013
Ames testNon AMES toxic0.6973
CarcinogenicityNon-carcinogens0.5412
BiodegradationNot ready biodegradable0.9675
Rat acute toxicity2.5425 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.863
hERG inhibition (predictor II)Non-inhibitor0.903
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral60 mg/1
Tablet, film coatedOral90 mg/1
TabletOral20 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Kit; tablet, delayed release; tablet, extended releaseOral
Tablet, extended releaseOral60 mg/60mg
Tablet, extended releaseOral20 mg
TabletOral10 mg
CapsuleOral10 mg/1
CapsuleOral20 mg/1
Capsule, liquid filledOral10 mg/1
Capsule, liquid filledOral20 mg/1
TabletOral30 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral60 mg/1
Tablet, extended releaseOral90 mg/1
Tablet, extended releaseOral10 mg
CapsuleOral10 mg
CapsuleOral5 mg
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Tablet, film coated, extended releaseOral90 mg/1
Prices
Unit descriptionCostUnit
Nifedipine powder15.3USD g
Procardia XL 90 mg 24 Hour tablet4.77USD tablet
Procardia xl 90 mg tablet4.58USD tablet
Procardia xl 60 mg tablet4.43USD tablet
Procardia XL 60 mg 24 Hour tablet4.13USD tablet
Adalat CC 90 mg 24 Hour tablet3.5USD tablet
Adalat cc 90 mg tablet3.37USD tablet
Adalat CC 60 mg 24 Hour tablet2.99USD tablet
Adalat cc 60 mg tablet2.87USD tablet
NIFEdipine CR Osmotic 90 mg 24 Hour tablet2.66USD tablet
Nifediac cc 90 mg tablet2.57USD tablet
Nifedipine er 90 mg tablet2.56USD tablet
Procardia xl 30 mg tablet2.56USD tablet
Procardia XL 30 mg 24 Hour tablet2.39USD tablet
NIFEdipine CR Osmotic 60 mg 24 Hour tablet2.38USD tablet
Nifedipine er 60 mg tablet2.29USD tablet
Afeditab cr 60 mg tablet2.24USD tablet
Nifediac cc 60 mg tablet2.17USD tablet
Adalat CC 30 mg 24 Hour tablet1.81USD tablet
NIFEdipine 20 mg capsule1.74USD capsule
Adalat cc 30 mg tablet1.61USD tablet
Adalat Xl 60 mg Extended-Release Tablet1.41USD tablet
NIFEdipine CR Osmotic 30 mg 24 Hour tablet1.35USD tablet
Adalat Xl 20 mg Extended-Release Tablet1.34USD tablet
Adalat Xl 30 mg Extended-Release Tablet1.34USD tablet
Nifedipine er 30 mg tablet1.32USD tablet
Afeditab cr 30 mg tablet1.26USD tablet
Mylan-Nifedipine Extended Release 60 mg Extended-Release Tablet1.18USD tablet
Procardia 10 mg capsule1.17USD capsule
Nifediac cc 30 mg tablet1.15USD tablet
NIFEdipine 10 mg capsule0.97USD capsule
Apo-Nifed 10 mg Capsule0.51USD capsule
Apo-Nifed 5 mg Capsule0.39USD capsule
Coral calcium plus 1500 mg caplet0.13USD caplet
Coral calcium 1000 mg caplet0.09USD caplet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5264446 No1993-11-232010-11-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point172-174 °CPhysProp
water solubilityInsolubleNot Available
logP2.20MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0177 mg/mLALOGPS
logP2.49ALOGPS
logP1.82ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)5.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity92.16 m3·mol-1ChemAxon
Polarizability33.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  3. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Li GR, Deng XL, Sun H, Chung SS, Tse HF, Lau CP: Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells. 2006 Jun;24(6):1519-28. Epub 2006 Feb 16. [PubMed:16484345 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC: Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001 Feb;85(2):816-27. [PubMed:11160515 ]
  2. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Bett GC, Rasmusson RL: Modification of K+ channel-drug interactions by ancillary subunits. J Physiol. 2008 Feb 15;586(4):929-50. Epub 2007 Dec 20. [PubMed:18096604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. doi: 10.1124/dmd.110.032094. Epub 2010 Mar 4. [PubMed:20203109 ]
  2. Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA: Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther. 2005 Apr;313(1):302-9. Epub 2005 Jan 5. [PubMed:15634941 ]
  3. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Teng S, Jekerle V, Piquette-Miller M: Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. [PubMed:14570758 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  3. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742 ]
  4. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
  6. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  7. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Payen L, Sparfel L, Courtois A, Vernhet L, Guillouzo A, Fardel O: The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol Toxicol. 2002;18(4):221-33. [PubMed:12206135 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23